about
The clinical potential of inotuzumab ozogamicin in relapsed and refractory acute lymphocytic leukemiaCharacteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors.Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib.Feasibility of therapy with hypomethylating agents in patients with renal insufficiencyImpact of Genetic Mutations and Health Plan Access to Therapies on Treatment Response and Drug Costs Related to Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myelogenous Leukemia.Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.Thrombocytopenia in patients with myelodysplastic syndromes.Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibSignificance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications.Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score systemOral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 studyRandomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes.Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 studyRigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial.Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia.Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation.Targeting the phosphoinositide 3-kinase pathway in hematologic malignanciesPredictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance.Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.Selecting the best frontline treatment in chronic myeloid leukemiaPharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia.A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromeTyrosine Kinase Inhibitors Early in the Disease Course: Lessons From Chronic Myelogenous LeukemiaInteractions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controlsPredictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure.Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers.Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blastCharacteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy.Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy.Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndromeFLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemiaAllogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control studyLow-dose azacitidine after allogeneic stem cell transplantation for acute leukemia
P50
Q26783425-8CD64A03-0D23-4A5E-89B8-638E2CD21862Q27851450-B7C9B27C-45FB-4CB2-ADCD-44BBC997CFBBQ27853179-A5B2F883-58D1-43E0-A314-30E39E891562Q28283836-2C3254F9-7A36-4B78-8E26-EE70DAD73384Q30488561-C4DD2F9B-7F2C-4713-9CBD-FD70FF2CB85EQ31033077-E66B9B12-4449-4217-8554-EBBAAC09F8A0Q33366921-7ECA5EF2-9DCF-4DA2-956B-D5E8897F6CC0Q33387517-8F4AC219-AFE5-4E89-A60F-B1A378539FC6Q33387519-4754B1F9-DC42-4831-B186-DF1078B877D7Q33390639-10174D7B-62D3-4523-B53C-5766B6893EDAQ33394812-5A2D4586-AE86-46EB-ABAD-63558F107274Q33395333-9E532931-068B-4E18-9E16-DD5851650264Q33399233-1E931C7D-7B22-422A-9222-B056F5E59480Q33403865-17312B3F-6F63-4747-8DB3-A9B911B66978Q33408184-4E942788-A65B-4850-8016-998E5A4AEC88Q33420436-5B2446E7-DB8F-48A4-B18E-2A0EE8E64A1CQ33425338-3B061803-CDD1-4AA0-8871-CDAB8C063F3EQ33430655-29EF6B39-DC04-4AA2-AF2F-DE3089B2F6E6Q33435191-A2AE9F4F-1CC6-43D7-9DE1-E7C2870C2DE2Q33443077-9F9C1B34-ECFF-4109-88CB-5874AC931D9EQ33558141-1F64C099-6666-48D4-861F-3F04DCE2DBD5Q33561227-7C4D478B-ACDF-4355-B3D8-3DD54984F2B4Q33561232-A9745D2F-9BC0-4503-8F4A-3C3109DF5EB6Q33702412-8ED0A2D3-5A58-47A3-A003-BD77D81CBF70Q33730841-8439B728-77BF-4CEE-8C6D-F4E459E05AF0Q33764253-9E8D3E59-3567-4E35-830E-5473B3D4F26BQ33764269-DEA4B614-B86B-4824-894E-188ED8554217Q33769335-7767407F-6D9E-4E9F-BDD3-904928BDB275Q33806617-0D075643-34A7-4153-AE8E-064EAE317E9FQ33840247-9D3E00EB-BCBE-4576-BB88-61205C2156CAQ33843390-24AE8276-9910-415C-97BA-B4393E59F932Q33843731-CEB645C5-0822-4799-8136-814E8A2A3C79Q33843996-5258F43B-6DF3-4F58-9FA4-F6848D2D67F1Q33844007-BB63A3DF-0286-4101-BA48-9D38343EAD64Q33844041-947734E2-08C5-4881-A338-9B1E7DB85A27Q33844109-68DE967A-5691-401B-96A4-1C1CC81C2EA2Q33856597-67518E8D-15A7-488F-B283-2E75D17C55AFQ33856839-493F0581-32F5-45F0-9DE9-412F503491FCQ33856972-351D22A4-6FC4-4510-8BAD-48761079B7D5Q33861150-31083AE0-2C84-4A34-90FF-635659BF4D1E
P50
name
Elias Jabbour
@ast
Elias Jabbour
@en
Elias Jabbour
@nl
type
label
Elias Jabbour
@ast
Elias Jabbour
@en
Elias Jabbour
@nl
prefLabel
Elias Jabbour
@ast
Elias Jabbour
@en
Elias Jabbour
@nl